Scinai Immunotherapeutics Ltd.
SCNI
$1.71
$0.010.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 269.00K | 269.00K | 386.50K | 386.50K | 206.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 269.00K | 269.00K | 386.50K | 386.50K | 206.00K |
| Cost of Revenue | 960.00K | 960.00K | 1.02M | 1.02M | 373.00K |
| Gross Profit | -691.00K | -691.00K | -635.00K | -635.00K | -167.00K |
| SG&A Expenses | 632.50K | 632.50K | 628.00K | 628.00K | 759.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.16M | 2.16M | 2.27M | 2.27M | 2.47M |
| Operating Income | -1.89M | -1.89M | -1.88M | -1.88M | -2.26M |
| Income Before Tax | -2.09M | -2.09M | -2.07M | -2.07M | -2.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.09M | -2.09M | -2.07M | -2.07M | -2.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.09M | -2.09M | -2.07M | -2.07M | -2.23M |
| EBIT | -1.89M | -1.89M | -1.88M | -1.88M | -2.26M |
| EBITDA | -1.53M | -1.53M | -1.53M | -1.53M | -1.76M |
| EPS Basic | -271.10K | -271.10K | -5.20K | -5.20K | -2.27M |
| Normalized Basic EPS | -4.24 | -4.24 | -0.81 | -0.81 | -85.92 |
| EPS Diluted | -271.10K | -271.10K | -5.20K | -5.20K | -2.27M |
| Normalized Diluted EPS | -4.24 | -4.24 | -0.81 | -0.81 | -85.92 |
| Average Basic Shares Outstanding | 307.90K | 307.90K | 1.59M | 1.59M | 123.60K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 300.00 | 300.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |